Adverse drug reactions in neonates: could we be documenting more?

References

• Geiling E, Cannon PR. Pathologic effects of elixir of sulfanilamide (diethylene glycol) poisoning: a clinical and experimental correlation: final report. JAMA 1938;111(10):919-26
   Google Scholar
• Lenz W, Knapp K. Thalidomide embryopathy. Arch Environ Occup Health 1962;5(2):14-19
   Google Scholar
• European Commission. The EU pharmacovigilance system. 2014. Available from: http://ec.europa.eu/health/human-use/pharmacovigilance/index_en.htm [Last accessed 1 August 2014]
   Google Scholar
• Turner MA, Hill H. Pharmacovigilance in neonatal intensive care. In: Mimouni F, Van Den Anker JN, editors. Neonatal pharmacology and nutrition update. Karger; Basel, Switzerland: 2015
   Google Scholar
• Lass J, Naelapää K, Shah U, et al. Hospitalised neonates in Estonia commonly receive potentially harmful excipients. BMC Pediatr 2012;12(1):136
   PubMedGoogle Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-5
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-19
   PubMed Web of Science ®Google Scholar
• Mitchell AA, Lacouture PG, Sheehan JE, et al. Adverse drug-reactions in children leading to hospital admission. Pediatrics 1988;82(1):24-9
   PubMedGoogle Scholar
• Gonzalez-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study. Int J Clin Pharmacol Ther 1998;36(10):530-3
   PubMedGoogle Scholar
• Martinez-Mir I, García-López M, Palop V, et al. A prospective study of adverse drug reactions in hospitalized children. Br J Clin Pharmacol 1999;47(6):681-8
   PubMedGoogle Scholar
• Davies EC, Christopher FG, Stephen T, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009;4(2):e4439
   PubMed Web of Science ®Google Scholar
• Thiesen S, Conroy EJ, Bellis JR, et al. Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children? a prospective observational cohort study of 6,601 admissions. BMC Med 2013;11(1):237
   PubMed Web of Science ®Google Scholar
• Knight M. Adverse drug reactions in neonates. J Clin Pharmacol 1994;34(2):128-35
   PubMedGoogle Scholar
• Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2012;68(1):21-8
   PubMedGoogle Scholar
• Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M. Adverse drug reactions and off label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. Br J Clin Pharmacol 2014;77(3):545-53
   PubMed Web of Science ®Google Scholar
• Bellis JR, Kirkham JJ, Thiesen S, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case? Control study of inpatients in a pediatric hospital. BMC Med 2013;11(1):238
   PubMedGoogle Scholar
• European Medicines Agency. Evidence of harm from off-label or unlicensed medicines in children. 2004. Available from: www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004021.pdf
   Google Scholar
• Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999;88(9):965-8
   PubMed Web of Science ®Google Scholar
• Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002;54(6):665-70
   PubMed Web of Science ®Google Scholar
• Ward RM, Benitz WE, Benjamin DK Jr, et al. Criteria supporting the study of drugs in the newborn. Clin Ther 2006;28(9):1385-98
   PubMedGoogle Scholar
• Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63(3):332-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Medication errors. 2012. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000570.jsp [Last accessed16 June 2014]
   Google Scholar
• International M.P. Off-label use and pharmacovigilance. Towards achieving business success. 2013;25
   Google Scholar
• Medicines and Healthcare Regulatory Agency (MHRA). How we regulate medicines. 2014. Available from: www.mhra.gov.uk/Howweregulate/Medicines/index.htm [Last accessed 6 June 2014]
   Google Scholar
• Waller P. Getting to grips with the new European Union pharmacovigilance legislation. Pharmacoepidemiol Drug Saf 2011;20(5):544-9
   PubMedGoogle Scholar
• Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001;52(1):77-83
   PubMed Web of Science ®Google Scholar
• Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002;110(5):e53-3
   PubMed Web of Science ®Google Scholar
• Mt-Isa S, Hallgreen CE, Wang N, et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf 2014;23(7):667-78
   PubMed Web of Science ®Google Scholar
• Schmidt B, Anderson PJ, Doyle LW, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012;307(3):275-82
   PubMed Web of Science ®Google Scholar
• Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357(19):1893-902
   PubMed Web of Science ®Google Scholar
• Whitelaw A, Jary S, Kmita G, et al. Randomized trial of drainage, irrigation and fibrinolytic therapy for premature infants with posthemorrhagic ventricular dilatation: developmental outcome at 2 years. Pediatrics 2010;125(4):e852-8
   PubMedGoogle Scholar
• Rashed AN, Wong IC, Cranswick N, et al. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol 2012;68(5):801-10
   PubMedGoogle Scholar
• Madadi P, Koren G, Cairns J, et al. Safety of codeine during breastfeeding fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007;53(1):33-5
   PubMedGoogle Scholar
• Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study. Clin Pharmacol Ther 2009;85(1):31-5
   PubMed Web of Science ®Google Scholar
• Gay KJ, Hill C, Bell T. Accuracy of drug-allergy recording in a District General Hospital. Int J Pharm Pract 2009;17(4):253-5
   PubMedGoogle Scholar
• Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf 2013;36(5):317-28
   PubMed Web of Science ®Google Scholar
• Goldstein LH, Berlin M, Saliba W, et al. Founding an adverse drug reaction (ADR) network: a method for improving doctors spontaneous ADR reporting in a general hospital. J Clin Pharmacol 2013;53(11):1220-5
   PubMedGoogle Scholar
• Hawcutt DB, Mainie P, Riordan A, et al. Reported paediatric adverse drug reactions in the UK 2000–2009. Br J Clin Pharmacol 2012;73(3):437-46
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez E, Herdeiro M, Figueiras A. Determinants of under-reporting of adverse drug reactions. Drug Saf 2009;32(1):19-31
   PubMed Web of Science ®Google Scholar
• Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions - The case of toxic epidermal necrolysis. Drug Saf 2004;27(7):477-87
   PubMed Web of Science ®Google Scholar
• Fletcher A. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med 1991;84(6):341-4
   PubMed Web of Science ®Google Scholar
• Star K, Norén GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children worldwide. Drug Saf 2011;34(5):415-28
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Drug Safety Communication: serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. 2011
   Google Scholar
• Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 2009;123(4):e609-13
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368(9536):704
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Codeine containing medicines. 2013
   Google Scholar
• Naidu RP. Causality assessment: a brief insight into practices in pharmaceutical industry. Perspect Clin Res 2013;4(4):233
   PubMedGoogle Scholar
• Arimone Y, Bégaud B, Miremont-Salamé G, et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol 2005;61(3):169-73
   PubMedGoogle Scholar
• Jones JK. Determining causation from case reports. In: Strom BL, editor. Pharmacoepidemiology. 4th edition. Wiley; NJ, USA: 2005. p. 555-70
   Google Scholar
• García-Cortés M, Lucena MI, Pachkoria K, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug induced liver injury. Aliment Pharmacol Ther 2008;27(9):780-9
   PubMed Web of Science ®Google Scholar
• Du W, Lehr VT, Lieh-Lai M, et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. J Clin Pharmacol 2013;53(1):87-95
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One 2011;6(12):e28096
   PubMed Web of Science ®Google Scholar
• Aurich-Barrera B, Wilton L, Brown D, Shakir S. Paediatric postmarketing pharmacovigilance using prescription-event monitoring. Drug Saf 2010;33(9):751-63
   PubMedGoogle Scholar
• Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation. Drug Saf 2000;22(2):161-8
   PubMed Web of Science ®Google Scholar
• Honigman B, Light P, Pulling RM, Bates DW. A computerized method for identifying incidents associated with adverse drug events in outpatients. Int J Med Inform 2001;61(1):21-32
   PubMed Web of Science ®Google Scholar
• Weiss J, Krebs S, Hoffmann C, et al. Survey of adverse drug reactions on a pediatric ward: a strategy for early and detailed detection. Pediatrics 2002;110(2):254-7
   PubMedGoogle Scholar
• Neubert A, Dormann H, Weiss J, et al. Are computerised monitoring systems of value to improve pharmacovigilance in paediatric patients? Eur J Clin Pharmacol 2006;62(11):959-65
   PubMed Web of Science ®Google Scholar
• Victor S, Dickinson H, Turner M. Plasma aminotransferase concentrations in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011;96(2):F144-5
   PubMedGoogle Scholar
• Vieux R, Hascoet JM, Merdariu D, et al. Glomerular filtration rate reference values in very preterm infants. Pediatrics 2010;125(5):e1186-92
   PubMed Web of Science ®Google Scholar
• Thayyil S, Sheik S, Kempley ST, Sinha A. A gestation-and postnatal age-based reference chart for assessing renal function in extremely premature infants. J Perinatol 2008;28(3):226-9
   PubMed Web of Science ®Google Scholar
• Allegaert K, Pauwels S, Smits A, et al. Enzymatic isotope dilution mass spectrometry (IDMS) traceable serum creatinine is preferable over Jaffe in neonates and young infants. Clin Chem Lab Med 2014;52(6):e107-9
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Poindexter B, Bidegain M, et al. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis 2012;55(11):1495-502
   PubMedGoogle Scholar
• Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999;341(16):1190-6
   PubMed Web of Science ®Google Scholar
• Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001;50(6):706-11
   PubMedGoogle Scholar
• de Graaf J, van Lingen RA, Valkenburg AJ, et al. Does neonatal morphine use affect neuropsychological outcomes at 8 to 9years of age? Pain 2013;154(3):449-58
   PubMed Web of Science ®Google Scholar
• Turner M, Duncan JC, Shah U, et al. Risk assessment of neonatal excipient exposure: lessons from food safety and other areas. Adv Drug Deliv Rev 2014;73:89-101
   PubMed Web of Science ®Google Scholar
• Hakkarainen KM, Andersson Sundell K, Petzold M, et al. Methods for assessing the preventability of adverse drug events. Drug Saf 2012;35(2):105-26
   PubMed Web of Science ®Google Scholar
• Sherwin CM, Medlicott NJ, Reith DM, Broadbent RS. Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child 2014;99(6):590-4
   PubMedGoogle Scholar
• McMahon AW, Levenson MS, McEvoy BW, et al. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics 2011;128(5):e1147-54
   PubMed Web of Science ®Google Scholar
• Baker-Smith C, Benjamin DK Jr, Califf RM, et al. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 2010;87(6):668-71
   PubMedGoogle Scholar
• Alvarez-Requejo A, Carvajal A, Bégaud B, et al. Under-reporting of adverse drug reactions - estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998;54(6):483-8
   PubMed Web of Science ®Google Scholar
• Kahn MG, Bailey LC, Forrest CB, et al. Building a common pediatric research terminology for accelerating child health research. Pediatrics 2014;133(3):516-25
   PubMedGoogle Scholar
• Battersby C, Santhakumaran S, Upton M, et al. The impact of a regional care bundle on maternal breast milk use in preterm infants: outcomes of the East of England quality improvement programme. Arch Dis Child Fetal Neonatal Ed 2014;99(5):F395-401
   PubMedGoogle Scholar
• Imperial College, London. Available from: www1.imperial.ac.uk/departmentofmedicine/divisions/infectiousdiseases/paediatrics/neonatalmedicine/ndau/
   Google Scholar
• Neonatal Data Analysis Unit. Annual Report. 2012. Available from: www1.imperial.ac.uk/resources/C8BA4C29-5A9A-4DE6-A0E9-DAF8BA9A80EA/ndau2012datadescriptionpopulationcharacteristicsv1.0.pdf [Last accessed 2 August 2014]
   Google Scholar
• Strom BL, Kimmel SE, Hennessy S. Textbook of pharmacoepidemiology. Wiley; NJ, USA: 2013
   Google Scholar
• Mirea L, Sankaran K, Seshia M, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr 2012;161(4):689-94. e1
   PubMed Web of Science ®Google Scholar
• Gagliardi L, Bellù R, Rusconi F, et al. Antenatal steroids and risk of bronchopulmonary dysplasia: a lack of effect or a case of over adjustment? Paediatr Perinat Epidemiol 2007;21(4):347-53
   PubMed Web of Science ®Google Scholar
• Rozé JC, Denizot S, Carbajal R, et al. Prolonged sedation and/or analgesia and 5-year neurodevelopment outcome in very preterm infants: results from the EPIPAGE cohort. Arch Pediatr Adolesc Med 2008;162(8):728-33
   PubMedGoogle Scholar
• d’Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17(19):2265-81
   PubMed Web of Science ®Google Scholar
• Neville KA, Becker ML, Goldman JL, Kearns GL. Developmental pharmacogenomics. Pediatr Anesth 2011;21(3):255-65
   PubMed Web of Science ®Google Scholar
• van Puijenbroek E, Conemans J, van Grootheest K. Spontaneous ADR reports as a trigger for pharmacogenetic research. Drug Saf 2009;32(3):255-64
   PubMedGoogle Scholar
• Leeder JS, Gaedigk R, Marcucci KA, et al. Variability of CYP3A7 expression in human fetal liver. J Pharmacol Exp Ther 2005;314(2):626-35
   PubMed Web of Science ®Google Scholar
• Johnson T, Tucker G, Rostami-Hodjegan A. Development of CYP2D6 and CYP3A4 in the first year of life. Clin Pharmacol Ther 2008;83(5):670-1
   PubMed Web of Science ®Google Scholar
• Howland RH. Pharmacogenetics and pharmacovigilance. Drug Saf 2009;32(3):265
   PubMed Web of Science ®Google Scholar
• Ross CJ, Carleton B, Warn DG, et al. Genotypic Approaches to Therapy in Children. Ann N Y Acad Sci 2007;1110(1):177-92
   PubMedGoogle Scholar
• Haller S, Spiegler J, Hemmelmann C, et al. Polymorphisms in FTO and maf genes and birth weight, BMI, ponderal index, weight gain in a large cohort of infants with a birth weight below 1500 grams. PLoS One 2013;8(6):e66331
   PubMedGoogle Scholar
• Arnott J, Hesselgreaves H, Nunn AJ, et al. Enhancing communication about paediatric medicines: lessons from a qualitative study of parents’ experiences of their child’s suspected adverse drug reaction. PLoS One 2012;7(10):e46022
   PubMedGoogle Scholar
• Subhedar NV, Parry HA. Critical incident reporting in neonatal practice. Arch Dis Child Fetal Neonatal Ed 2010;95(5):F378-82
   PubMedGoogle Scholar
• Huskins WC. Quality improvement interventions to prevent healthcare-associated infections in neonates and children. Curr Opin Pediatr 2012;24(1):103-12
   PubMedGoogle Scholar
• Ellsbury DL, Ursprung R. A quality improvement approach to optimizing medication use in the neonatal intensive care unit. Clin Perinatol 2012;39(1):1-10
   PubMedGoogle Scholar
• Frey B, Schwappach D. Critical incident monitoring in paediatric and adult critical care: from reporting to improved patient outcomes? Curr Opin Crit Care 2010;16(6):649-53
   PubMedGoogle Scholar
• Napoleone E. Children and ADRs (adverse drug reactions). Ital J Pediatr 2010;36:4
   Google Scholar
• WHO. Promoting safety of medicines for children. WHO; Geneva, Switzerland: 2007
   Google Scholar
• Committee For Medicinal Products For Human Use (CHMP). Guideline on conduct of pharmacovigilance for medicines used by the paediatric population. EMEA/CHMP/PhVWP/235910/2005, rev. 1
   Google Scholar
• Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281(9):824-9
   PubMed Web of Science ®Google Scholar
• Castro-Pastrana L, Carleton BC. Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. J Popul Ther Clin Pharmacol 2010;18:e76-88
   Google Scholar
• Turner M, Catapano M, Hirschfeld S, Giaquinto C. Paediatric drug development: the impact of evolving regulations. Adv Drug Deliv Rev 2014;73:2-13
   PubMed Web of Science ®Google Scholar
• Steadman E, Raisch DW, Bennett CL, et al. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother 2010;54(4):1534-40
   PubMedGoogle Scholar
• Laptook A, Rosenfeld C. Chloral hydrate toxicity in a preterm infant. Pediatr Pharmacol (New York, NY) 1983;4(3):161-5
   Google Scholar
• Mayers D, Hindmarsh KW, Sankaran K, et al. Chloral hydrate disposition following single-dose administration to critically ill neonates and children. Dev Pharmacol Ther 1991;16(2):71
   PubMedGoogle Scholar
• HYDRATE C. Use of chloral hydrate for sedation in children. Pediatrics 1993;92(3):471
   PubMedGoogle Scholar
• Sutherland JM, et al. Toxicity of chloramphenicol for the newborn infant. In: AMER Medical Assoc; Chicago, IL, USA; AMA J Dis Child 1959
   Google Scholar
• Burns LE, Hodgman JE, Cass AB. Fatal circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med 1959;261(26):1318-21
   PubMedGoogle Scholar
• Balbi HJ, Chloramphenicol A. Review. Pediatr Rev 2004;25(8):284-8
   PubMed Web of Science ®Google Scholar
• Madadi P, Moretti M, Koren G. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009;55(11):1077-8
   PubMed Web of Science ®Google Scholar
• Clark RH, Thomas P, Peabody J. Extrauterine growth restriction remains a serious problem in prematurely born neonates. Pediatrics 2003;111(5):986-90
   PubMed Web of Science ®Google Scholar
• Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005;116(1):1-7
   PubMed Web of Science ®Google Scholar
• Baud O. Postnatal steroid treatment and brain development. Arch Dis Child Fetal Neonatal Ed 2004;89(2):F96
   PubMedGoogle Scholar
• Leipälä JA, Raivio KO, Sarnesto A, et al. Intrauterine growth restriction and postnatal steroid treatment effects on insulin sensitivity in preterm neonates. J Pediatr 2002;141(4):472-6
   PubMedGoogle Scholar
• Walsh MC, Yao Q, Horbar JD, et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006;118(5):e1328-35
   PubMedGoogle Scholar
• Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011;306(1):70-8
   PubMedGoogle Scholar
• Rosenvinge MM, Doerholt K. HIV in mothers and children. Medicine 2013;41(8):461-5
   Google Scholar
• Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009;10(10):591-613
   PubMedGoogle Scholar
• Van Overmeire B, Smets K, Van de Broek H, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000;343(10):674-81
   PubMed Web of Science ®Google Scholar
• Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002;161(4):202-7
   PubMed Web of Science ®Google Scholar
• Gouyon J, Guignard J. Management of acute renal failure in newborns. Pediatr Nephrol 2000;14(10-11):1037-44
   PubMedGoogle Scholar
• Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 1994;36(6):724-31
   PubMed Web of Science ®Google Scholar
• Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med 1992;326(16):1050-4
   PubMed Web of Science ®Google Scholar
• Oxygen saturation and outcomes in preterm infants. N Engl J Med 2013;368(22):2094-104
   PubMed Web of Science ®Google Scholar
• Wadsworth SJ, Suh B. In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns. Antimicrob Agents Chemother 1988;32(10):1571-5
   PubMed Web of Science ®Google Scholar
• Silverman WA, Blanc WA, Crozier DN, Silverman WA. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956;18(4):614-25
   PubMedGoogle Scholar
• Choonara I. Educational Paper: aspects of clinical pharmacology in children—pharmacovigilance and safety. Eur J Pediatr 2013;172(5):577-80
   PubMedGoogle Scholar
• Roberts RJ. Drug therapy in infants: pharmacologic principles and clinical experience. WB Saunders; Philadelphia, PA, USA: 1984
   Google Scholar
• Bendapudi P, Barr S. Diagnosis and management of pulmonary hypertension of the newborn. Paediatrics Child Health 2014;24(1):12-16
   Google Scholar
• Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants (review). Cochrane Database Syst Rev 2003(4):CD003665
   Google Scholar
• Bell EF, Hansen NI, Brion LP, et al. Serum tocopherol levels in very preterm infants after a single dose of vitamin E at birth. Pediatrics 2013;132(6):e1626-33
   PubMedGoogle Scholar
• Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med 2009;10(2):256-9
   PubMedGoogle Scholar
• Zosel A, Egelhoff E, Heard K. Severe lactic acidosis from iatrogenic propylene glycol overdose. Pharmacotherapy 2010;30(2):219
   PubMedGoogle Scholar
• Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving iv benzodiazepines case series and prospective, observational pilot study. Chest 2005;128(3):1674-81
   PubMedGoogle Scholar
• Whittaker A, Currie AE, Turner MA, et al. Toxic additives in medication for preterm infants. Arch Dis Child Fetal Neonatal Ed 2009;94(4):F236-40
   PubMedGoogle Scholar